Panobinostat for the treatment of relapsed or relapsed/refractory multiple myeloma: pharmacology and clinical outcomes
- PMID: 26503877
- DOI: 10.1586/17512433.2016.1096773
Panobinostat for the treatment of relapsed or relapsed/refractory multiple myeloma: pharmacology and clinical outcomes
Abstract
Recently, outcomes for patients with multiple myeloma have improved dramatically due to improved and innovative therapies. However, most patients will either relapse or become refractory to current therapy. Thus, a significant unmet need remains for novel agents to treat this patient population. Panobinostat, a potent pan-deacetylase inhibitor with a unique mechanism of action targeting both epigenetic regulation of gene expression and protein metabolism, has preclinical synergy with a number of agents, including the proteasome inhibitor bortezomib. In a phase 3 trial of panobinostat with bortezomib and dexamethasone, addition of panobinostat significantly prolonged the median progression-free survival of patients with relapsed or relapsed and refractory multiple myeloma. This review focuses on clinical development of panobinostat, with particular emphasis on pharmacokinetics and adverse event management.
Keywords: bortezomib; deacetylase inhibitors; multiple myeloma; panobinostat; relapsed and refractory multiple myeloma.
Similar articles
-
Deacetylase inhibitors: an advance in myeloma therapy?Expert Rev Hematol. 2017 Mar;10(3):229-237. doi: 10.1080/17474086.2017.1280388. Epub 2017 Feb 1. Expert Rev Hematol. 2017. PMID: 28076695 Review.
-
Panobinostat for the management of multiple myeloma.Future Oncol. 2017 Mar;13(6):477-488. doi: 10.2217/fon-2016-0329. Epub 2016 Oct 25. Future Oncol. 2017. PMID: 27776419 Review.
-
Panobinostat PK/PD profile in combination with bortezomib and dexamethasone in patients with relapsed and relapsed/refractory multiple myeloma.Eur J Clin Pharmacol. 2016 Feb;72(2):153-61. doi: 10.1007/s00228-015-1967-z. Epub 2015 Oct 22. Eur J Clin Pharmacol. 2016. PMID: 26494130 Free PMC article. Clinical Trial.
-
Panobinostat for the Treatment of Multiple Myeloma.Clin Cancer Res. 2015 Nov 1;21(21):4767-73. doi: 10.1158/1078-0432.CCR-15-0530. Epub 2015 Sep 11. Clin Cancer Res. 2015. PMID: 26362997 Review.
-
Panobinostat: a novel pan-deacetylase inhibitor for the treatment of relapsed or relapsed and refractory multiple myeloma.Expert Rev Anticancer Ther. 2015;15(7):737-48. doi: 10.1586/14737140.2015.1047770. Epub 2015 Jun 7. Expert Rev Anticancer Ther. 2015. PMID: 26051506 Review.
Cited by
-
Practical guidance for new multiple myeloma treatment regimens: A nursing perspective.Semin Oncol. 2022 Feb;49(1):103-117. doi: 10.1053/j.seminoncol.2022.01.010. Epub 2022 Feb 10. Semin Oncol. 2022. PMID: 35197198 Free PMC article. Review.
-
Recent developments in epigenetic cancer therapeutics: clinical advancement and emerging trends.J Biomed Sci. 2021 Apr 12;28(1):27. doi: 10.1186/s12929-021-00721-x. J Biomed Sci. 2021. PMID: 33840388 Free PMC article. Review.
-
Design, Synthesis, and Biological Evaluation of 2,4-Imidazolinedione Derivatives as HDAC6 Isoform-Selective Inhibitors.ACS Med Chem Lett. 2019 Jul 5;10(8):1122-1127. doi: 10.1021/acsmedchemlett.9b00084. eCollection 2019 Aug 8. ACS Med Chem Lett. 2019. PMID: 31413795 Free PMC article.
-
MPT0G413, A Novel HDAC6-Selective Inhibitor, and Bortezomib Synergistically Exert Anti-tumor Activity in Multiple Myeloma Cells.Front Oncol. 2019 Apr 9;9:249. doi: 10.3389/fonc.2019.00249. eCollection 2019. Front Oncol. 2019. PMID: 31024851 Free PMC article.
-
Targeting EZH2 in Multiple Myeloma-Multifaceted Anti-Tumor Activity.Epigenomes. 2018 Sep;2(3):16. doi: 10.3390/epigenomes2030016. Epub 2018 Sep 3. Epigenomes. 2018. PMID: 30761216 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
